NASDAQ$EYPT
EyePoint Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Announced first quarter 2024 financial results and highlighted recent corporate developments.
EyePoint Pharmaceuticals reported total net revenue of $11.7 million for the first quarter ended March 31, 2024, compared to $7.7 million for the same period in 2023. The company's operating expenses totaled $45.0 million, and net loss was $29.3 million, or ($0.55) per share. Cash and investments totaled $299.3 million as of March 31, 2024.
- The company is on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024.
- Cash and investments were $299 million as of March 31, 2024, providing a cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026.
- The company plans to assess the full twelve-month study results of the Phase 2 PAVIA clinical trial of DURAVYU™ in non-proliferative diabetic retinopathy (NPDR) to evaluate the path forward for DURAVYU as a potential treatment for NPDR.
- EyePoint plans to host an R&D Day on June 26, 2024, in New York City.
Headline financials
Revenue & EPS history
EyePoint Pharmaceuticals · Revenue · Quarterly
$11.7M
Revenue by segment
EyePoint Pharmaceuticals · $15.2M total across 2 segments · Q3 2023
- License and Royalties$14.4M+27565.4%94.6%
- Product sales, net$816K-91.6%5.4%
Forward guidance
The company expects its cash, cash equivalents, and investments as of March 31, 2024, will enable it to fund operations through topline data for the planned Phase 3 clinical trials of DURAVYU for wet AMD in 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.4%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
48%
28 / 58 earnings
Positive
+21.1%
Q3 2023
Best reaction
-37.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +1.9% | -11.9% | |
| Q4 2025 | -1.9% | -14.5% | -26.9% | |
| Q3 2025 | -11.0% | -8.4% | +43.2% | |
| Q1 2025 | -2.2% | -6.4% | +43.0% | |
| Q4 2024 | +8.2% | +16.6% | -24.2% | |
| Q3 2024 | -3.7% | -8.0% | -27.9% | |
| Q2 2024 | +1.6% | -7.3% | -11.6% | |
| Q1 2024 | +6.7% | +2.9% | -23.3% | |
| Q4 2023 | -5.2% | -11.4% | -21.2% | |
| Q3 2023 | +21.1% | +26.7% | +9.8% | |
| Q2 2023 | -1.3% | -2.6% | -17.2% | |
| Q1 2023 | +4.5% | -0.3% | -7.9% | |
| Q4 2022 | +2.8% | -0.9% | -7.3% | |
| Q3 2022 | -1.3% | -3.5% | -37.5% | |
| Q2 2022 | +13.3% | +14.2% | -0.2% | |
| Q1 2022 | -4.9% | -19.5% | -23.8% | |
| Q4 2021 | +16.6% | +34.3% | +23.9% | |
| Q3 2021 | +10.1% | +26.1% | +18.6% | |
| Q2 2021 | +6.5% | +8.3% | +28.7% | |
| Q1 2021 | -8.1% | -14.8% | -12.0% | |
| Q4 2020 | -18.6% | -12.4% | -6.8% | |
| Q3 2020 | -7.5% | +10.0% | +30.0% | |
| Q2 2020 | -8.2% | -6.8% | -32.9% | |
| Q1 2020 | -3.3% | -2.2% | -8.9% | |
| Q4 2019 | -11.1% | -27.1% | -47.2% | |
| Q3 2019 | -37.2% | -41.6% | -35.1% | |
| Q2 2019 | +11.9% | +3.2% | +20.6% | |
| Q4 2018 | -3.5% | +2.2% | +41.0% | |
| Q3 2018 | +6.7% | -15.9% | -4.6% | |
| Q2 2018 | -2.7% | -5.5% | +12.7% | |
| Q1 2018 | -2.4% | +9.5% | +0.8% | |
| Q4 2017 | +1.6% | -5.5% | -3.1% | |
| Q3 2017 | +16.6% | +17.8% | +33.1% | |
| Q2 2017 | +4.1% | +5.3% | +0.0% | |
| Q1 2017 | +1.0% | -2.0% | -11.2% | |
| Q4 2016 | +1.6% | -4.1% | -35.7% | |
| Q3 2016 | +0.7% | — | — | |
| Q2 2016 | -10.1% | — | — | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | -12.3% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +2.2% | — | — | |
| Q2 2014 | +4.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q3 2012 | +2.1% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -6.9% | — | — | |
| Q3 2011 | -5.5% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -1.7% | — | — | |
| Q1 2010 | -4.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro